Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
3,128.00    44.00 (1.43%)
Bid:
3,126.00
Ask:
3,129.00
Spread: 3.00 (0.096%)
Market Cap: £4.36b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

Q2 Pre-Close Trading Update

24 Jun 2014 07:00

RNS Number : 3241K
Croda International PLC
24 June 2014
 



Croda International Plc ('Croda')

Quarter Two 2014 Pre-Close Trading Update

Before entering its close period ahead of reporting its interim results for the six months ending June 30 2014 on July 22 2014, Croda announces the following update on current trading.

At the time of its Interim Management Statement on April 24 2014, the Group said that it expected second quarter performance to be similar to the first quarter, where it reported pre-tax profits of £65.2 million. The Group also highlighted that adverse currency translation was expected to remain an issue.

The modestly improving underlying sales trend seen in recent quarters in our core Consumer Care and Performance Technologies divisions has continued into the current period, though market conditions remain subdued especially in Europe. However, sales were weaker in Industrial Chemicals. In addition, greater transactional currency costs and a slightly less favourable product mix in Consumer Care than that seen in the first quarter mean that quarter two margins are now likely to be lower than quarter one.

Sterling has strengthened further in recent months resulting in an adverse currency translation and transaction impact of approximately £6.5m year-on-year on second quarter pre-tax profits, greater than originally expected.

Croda now expects quarter two pre-tax profits to be approximately 8% below its pre-tax profit performance in quarter one due to a combination of these factors. Approximately £1.5m of the difference between quarters is due to the increase in the strength of sterling.

Operating cash generation in the quarter is expected to be very strong.

For the full year, if sterling remains at current levels, the currency translation and transaction effects we are seeing would have reduced the £251.4m pre-tax profit reported in 2013 by approximately £19m (£13m currency translation plus an estimated £6m currency transaction, arising mainly on Croda's US dollar denominated exports from Europe). Whilst we still expect to achieve underlying profit progress in 2014, pre-tax profits are now expected to come in below those attained in 2013.

The Board remains confident in the long term strategy of the group and its medium term targets remain unchanged.

 

-ENDS-

 

Enquiries:

 

 

Sean Christie, Group Finance Director

Tel: 01405 860551

Charles Armitstead, Pendomer Communications

Tel: 0203 603 5220

 

Sean Christie, Group Finance Director, will host a conference call for analysts at 8.00am today. Please dial +44 (0) 203 426 2886 and quote "Croda International" to gain access to the call.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBIGDLUGDBGSX
Date   Source Headline
11th Jun 20262:58 pmRNSDirector/PDMR Shareholding
11th Jun 20269:15 amRNSDirector Declaration
1st Jun 20261:46 pmRNSDirector/PDMR Shareholding
29th May 20264:06 pmRNSDirector/PDMR Shareholding
29th May 20263:10 pmRNSDirector/PDMR Shareholding
29th May 20261:53 pmRNSDirector/PDMR Shareholding
29th May 20261:52 pmRNSDirector/PDMR Shareholding
29th May 20261:45 pmRNSDirector/PDMR Shareholding
15th May 20269:23 amRNSDirector/PDMR Shareholding
12th May 202612:10 pmRNSDirector/PDMR Shareholding
6th May 20261:21 pmRNSDirector/PDMR Shareholding
23rd Apr 202611:20 amRNSResult of AGM
22nd Apr 20267:00 amRNSFirst quarter 2026 sales in line with expectations
13th Apr 20261:41 pmRNSDirector/PDMR Shareholding
31st Mar 202611:48 amRNSHolding(s) in Company
26th Mar 20264:34 pmRNSDirector/PDMR Shareholding
18th Mar 20263:31 pmRNSDirector/PDMR Shareholding
18th Mar 20263:30 pmRNSDirector/PDMR Shareholding
18th Mar 20263:27 pmRNSDirector/PDMR Shareholding
18th Mar 20263:25 pmRNSDirector/PDMR Shareholding
18th Mar 20263:23 pmRNSDirector/PDMR Shareholding
18th Mar 20263:23 pmRNSDirector/PDMR Shareholding
18th Mar 20263:20 pmRNSDirector/PDMR Shareholding
16th Mar 20261:36 pmRNSAnnual Financial Report
16th Mar 20261:36 pmRNSAnnual Financial Report
11th Mar 202611:28 amRNSDirector/PDMR Shareholding
11th Mar 202611:28 amRNSDirector/PDMR Shareholding
6th Mar 20261:32 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:13 pmRNSHolding(s) in Company
24th Feb 20267:00 amRNSResults for the year ended 31 December 2025
11th Feb 20262:59 pmRNSDirector/PDMR Shareholding
13th Jan 20262:47 pmRNSDirector/PDMR Shareholding
9th Jan 20267:00 amRNSDirector Declaration
11th Dec 202511:30 amRNSDirector/PDMR Shareholding
11th Nov 202511:19 amRNSDirector/PDMR Shareholding
16th Oct 20257:00 amRNSThird quarter 2025 sales update
14th Oct 20251:58 pmRNSDirector/PDMR Shareholding
8th Oct 20254:26 pmRNSDirector/PDMR Shareholding
1st Oct 20253:45 pmRNSDirector/PDMR Shareholding
18th Sep 20253:49 pmRNSHolding(s) in Company
12th Sep 202510:11 amRNSDirector/PDMR Shareholding
11th Sep 20253:54 pmRNSDirector/PDMR Shareholding
29th Aug 20253:58 pmRNSHolding(s) in Company
29th Aug 202511:03 amRNSHolding(s) in Company
27th Aug 20251:58 pmRNSHolding(s) in Company
22nd Aug 20254:24 pmRNSDirector/PDMR Shareholding
22nd Aug 202511:55 amRNSDirector/PDMR Shareholding
14th Aug 20259:10 amRNSDirector/PDMR Shareholding
12th Aug 202511:42 amRNSDirector/PDMR Shareholding
7th Aug 20259:16 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.